Library · Brain & nerves · Neuroprotection and cognitive function enhancement
Cerebrolysin
FPF-1070, Cerebrolysinum, Brain-derived neurotrophic peptides
Neuropeptide mixture from purified porcine brain proteins, used clinically in 50+ countries for acute ischemic stroke, traumatic brain injury, and dementia, though not FDA-approved. Recent systematic reviews (2023–2024) give mixed results on stroke efficacy, keeping its evidence base debated.
Research score 80/100. Reference only, not a dose.
- Neuroprotective
- Cognitive Enhancement
- Memory Enhancement
- Focus Enhancement
- BDNF Increase
- Neurogenesis
- US status
- Not FDA Approved
- Approval
- Approved in many countries (e.g., Russia, China, Germany, Austria); Not FDA Approved in the USA.
- Evidence
- Numerous clinical trials. A 2023 Cochrane review found little to no benefit in preventing death from acute ischemic stroke, while a 2024 assessment suggested benefits in neurological recovery. The overall strength of evidence is still debated.
- Research score
- 80 / 100
- Indication
- Multiple Approved Indications
- Origin
- Austria
- Source category
- Brain & Nervous System
- Status group
- Investigational
Mechanism
Contains fragments resembling BDNF, GDNF, NGF, and CNTF; crosses the blood-brain barrier to activate BDNF/TrkB and PI3K/Akt signaling for neuron survival and plasticity, supports synaptic remodeling via MAPK/ERK, and curbs inflammation and glutamate-driven excitotoxicity.
Safety file
Generally has a strong safety record, though some data suggest higher doses in acute stroke may raise non-fatal serious adverse events.
- Injection site reactions
- Headache
- Dizziness
- Agitation
- Nausea
- Feeling hot